Navigation Links
Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer

Researchers have found that aromatase inhibitors like anastrozole are more effective in treating postmenopausal women with hormone receptor-positive early breast cancer// than tamoxifen according to study published in the "The Lancet Oncology" journal.

Researchers followed more than 6,000 postmenopausal women with early breast cancer for more than 5 years and found that patients on anastrozole had much less adverse effects and the drug was well tolerated by patients.

Majority of adverse effects with tamoxifen occurred during the first 2.5 years of treatment leading to patients withdrawing from treatment, but this was much less in patients on anastrozole. The drug also had a significantly better risk-benefit profile one to two years after treatment when compared to tamoxifen.

This has led to the conclusion that aromatase inhibitors are more effective for initial treatment after surgery than tamoxifen for treating postmenopausal women with early hormone receptor-sensitive breast cancer.


'"/>




Page: 1

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. Early Switch to an Aromatase Inhibitor Increases Survival
3. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
4. LipB Protein Inhibitors Help To Fight Against TB
5. ACE Inhibitors For Vascular Disease Patients
6. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
7. Better prostate cancer detection
8. Better Treatment for obesity
9. For a Better Memory
10. Baby Talk Better Than Adult Speech
11. Drug Combo Works Better for children with ADHD, Tics

Post Your Comments:
(Date:11/9/2009)...na, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray ...ing developer, manufacturer and,marketer of medica...unaudited,financial results for the third quarter ...Highlights for Operations as of September 30, 2009...1 million, an increase of, 3.1% over the thi...
(Date:11/9/2009)...ks President Obama,s promise to not expand abortio... Bishops still concerned for poor, elderly ,, ...inal Francis George of Chicago, president of the U...d the November 7 decision of the U.S. House of Rep...oney from paying for elective abortions. ,, In...
(Date:11/9/2009)... Studying Genetic Variance Across the World is C... (Vocus) November 9, 2009 --...xtraordinarily valuable when analyzing and interpr...ics study that scanned the genomes of 4,000 peopl...rences, Drs. Chao Tian and Michael F. Seldin of th...
(Date:11/9/2009)...new cells regained sexual function, study says,...Researchers were able to restore sexual function t...le tissue in the lab and implanting it, a new stud...ys off, researchers say the technique could one da...men. , "We were able to show the tissue was abl...
(Date:11/9/2009)... Course, to be Offered in April 2010, Provides F... Cambridge, MA (Vocus) November 9,...an Rights (PHR) first inspected a suspected mass ...d he would need a team of experts to help interpre...perly was a key first step in securing evidence of...
Breaking Medicine News(10 mins):Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:News from the November/December Issue of Molecular Medicine 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4
...N.J., Dec. 12 Alfacell Corporation (Nasdaq: AC...president, chief financial officer and corporate s...s of today. Mr. Kenyon will remain on the board o... Kenyon has accepted a full time position as execu...
...ass., Dec. 12 Millennium Research Group (MRG) ana...ished G lobal Markets for Hyaluronic Acid Viscos...fer extensive expertise on the recent FDA premarke...s available to comment on: , , , , ...
..., Dec. 12 Ogilvy Public Relations Worldwide (Ogi... announced today that it has been awarded a five-y...with the National Cancer Institute (NCI), Office o...,s life sciences consulting subsidiary, Feinstein ...
...hase 3 Program Expected to Begin in December - , ...rmaceuticals, a division of Wyeth (NYSE: WYE ), ...inical trial of neratinib (HKI-272) in women with ...the ErbB-2 receptor (also known as HER-2 or Neu). ...
...s not sure whether one causes the other, or one is...2 (HealthDay News) -- Adults who have panic disord...t attacks and heart disease, but not heart-related...than 347,000 adults without the condition. , Peopl...
...ec. 12 The Female Health Company (NYSE Alternex...Administration,s (FDA) Obstetrics and Gynecology D...at the company,s second-generation female condom, ...ondition that the FC2 Female Condom,s instructions...
Other Medicine News:Health News:Alfacell Announces Management Update 2Health News:Alfacell Announces Management Update 3Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:Panic Disorder Linked to Higher Risk of Heart Disease 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5
(Date:11/9/2009)..., NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ ...ay announced its schedule of events at the 38th an...logy (AAGL), which runs from November 15-19 in Orl...will be presented featuring the Company,s Urology/...truction systems and mid-urethral sling systems us...
(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCa...E: AOB ), ("the Company" or "AOBO"), a pharmaceut... the development, manufacture and,commercializatio...unter ("OTC"),products, today announced that it pl...s on Monday, November 16, 2009, after the market c...
(Date:11/9/2009)..., SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall...today reported financial results for the third qua...d a lower net loss allocable to common stockholder...r $0.38 per share, compared to a net loss allocabl...008 of $56.2 million, or $0.76 per share, and a ne...
Breaking Medicine Technology:Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Exercise 30 Minutes a Day 3F Who Knew 21 58468 1Exercise 30 Minutes a Day 3F Who Knew 21 58468 2Boston University School of Medicines black womens health study receives 249 1 million award 58465 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 2Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 3Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 4
EBI OsteoGen™-M (Mesh Cathode)
Interference Screws
...crew is indicated for graft fixation in Orthopaedi...s with bone-patellar tendon-bone or soft tissue au...es easy and atraumatic insertions with excellent g...-Reinforced 96L/4D copolymer combines optimal stre...
PHANTOM SofThread Cannulated Interference Screws
Medicine Products: